Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo Nordisk's Wegovy pill for obesity.
An AstraZeneca breast cancer drug received a positive opinion from European regulators, despite an FDA advisory committee voting against the drug last month. Novo Nordisk’s …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
EU and US advisers split over AstraZeneca breast cancer drug
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
AstraZeneca picks up FDA approval for hypertension drug
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
Europa dá sinal verde para pílula Wegovy e terapias inovadoras contra câncer e hepatite C
Roche narrowly edges out AstraZeneca for the top-rated oncology MSL team: survey
EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug - The Korea Times
